Project Grant HT9425261E228
Award Date 6/15/26
Completion Date 6/14/30
Dollars Obligated $3M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Sudbury, MA 01776, USA
Similar Awards
- Federal Grant Award Summary Byomass Inc. received a $694,935 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective November 1, 2025, through October 31, 2027. The award supports the development of BYOM-1119, a novel therapeutic candidate designed for the prevention and treatment of pancreatic cancer metastases and cachexia. The research and development activities will be conducted at the company's facility in...
- This federal Project Grant award from the Department of Defense's Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) provides $1,383,586.00 to Byomass Inc. to support the development of BYOM-0322, a novel biologic agent targeting the TGF-beta superfamily. The purpose is to evaluate BYOM-0322 for the prevention and treatment of breast cancer metastases and cancer cachexia (muscle wasting). This 3-year grant, awarded on February 15, 2024, will fund Byomass...
- Federal Grant Award Summary The Trustees of Boston University received a $1.399 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for research on ubiquitin-independent targeted protein degraders for beta-catenin. The award, initiated July 15, 2026, and scheduled for completion by July 14, 2029, will deliver basic and applied biomedical research services aimed at developing innovative therapeutic approaches. This...
- Federal Project Grant Award Summary Dionysus Digital Health Inc. received a $4.03 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct a prospective validation study of the ENLIGHTEN device for predicting postpartum depression. The award, issued September 1, 2025, with an ultimate completion date of August 31, 2029, funds a four-year research initiative utilizing at-home sample collection methods...
- Federal Grant Award Summary Asedasciences Inc. received a $1,050,320 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on September 30, 2025, with an ultimate completion date of September 29, 2028. The awardee will develop a high-throughput cellular and biomimetic screening platform integrated with machine learning analytics and data visualization capabilities designed to assess neurotoxicity risk. This platform...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $559,997 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2026 through June 30, 2028. The award supports research and development activities focused on novel small molecule targeting of mitochondrial lipoylation in colorectal cancer. This research initiative aligns with the DHA's mission to transform...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Massachusetts General Hospital (MGH) a $1.35M Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025 through June 30, 2029. The award funds research investigating metabolites and metabolic pathways in relation to Crohn disease risk, with research activities conducted at MGH's Boston, Massachusetts location. This biomedical research initiative aligns with the DHA's...
- Federal Project Grant Award Summary Young Biopharma, LLC received a $4.32 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to develop YB-16, a novel transient receptor potential (TRP) channel modulator for the treatment of osteoarthritis knee pain. The award was obligated on June 15, 2025, with a performance period extending through June 14, 2028. The research will be conducted at the awardee's facility in...
- Federal Grant Award Summary 149 Bio LLC received a $5.1M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period July 1, 2025 through June 30, 2029. The award supports the development of a myeloid-targeted novel therapeutic intervention for glomerular diseases. This research initiative will be conducted at the awardee's facility in Miami, FL and aims to advance biomedical solutions relevant to military health...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded $3.16M under the Military Medical Research and Development program (CFDA 12.420) to Eg427 on July 1, 2025, for a first-in-human (FIH) Phase 1B/2A dose escalation clinical study evaluating EG110A, a nonreplicative Herpes Simplex Virus 1 (HSV-1)-derived gene therapy. The study, which will be conducted in France and is scheduled for completion by June 30, 2028, investigates the safety and efficacy of intradetrusor injections of...